Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients

Abstract

Red blood cells (RBC) transfusion is used to alleviate symptoms and prevent complications in anemic patients by restoring oxygen delivery to tissues. RBC transfusion efficacy, that can be measured by a rise in hemoglobin (Hb) concentration, is influenced by donor‐, product‐, and recipient‐related characteristics. In some studies, severe pre‐transfusion anemia is associated with a greater than expected Hb increment following transfusion but the biological mechanism underpinning this relationship remains poorly understood. We conducted a prospective study in critically ill patients and quantified Hb increment following one RBC transfusion. In a murine model, we investigated the possibility that, in conjunction with the host erythropoietic response, the persistence of transfused donor RBC is improved to maintain a highest RBC biomass. We confirmed a correlation between a greater Hb increment and a deeper pre‐transfusion anemia in a cohort of 17 patients. In the mouse model, Hb increment and post‐transfusion recovery were increased in anemic recipients. Post‐transfusion RBC recovery was improved in hypoxic mice or those receiving an erythropoiesis‐stimulating agent and decreased in those treated with erythropoietin (EPO)‐neutralizing antibodies, suggesting that EPO signaling is necessary to observe this effect. Irradiated recipients also showed decreased post‐transfusion RBC recovery. The EPO‐induced post‐transfusion RBC recovery improvement was abrogated in irradiated or in macrophage‐depleted recipients, but maintained in splenectomized recipients, suggesting a mechanism requiring erythroid progenitors and macrophages, but which is not spleen‐specific. Our study highlights a physiological role of EPO in downregulating post‐transfusion RBC clearance, contributing to maintain a vital RBC biomass to rapidly cope with hypoxemia.